Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/23/2022 | Buy → Neutral | BTIG |
BTIG downgraded Zosano Pharma from Buy to Neutral
Maxim Group reiterated coverage of Zosano Pharma with a rating of Buy and set a new price target of $2.50 from $1.50 previously
FREMONT, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced changes to its board of directors, including the appointment of Elaine M. Yang. "We are pleased to welcome Elaine, a high caliber executive, to our board of directors," said Steven Lo, president and chief executive officer of Zosano. "Elaine has deep and broad executive leadership experience, building and running cross functional departments, including business operations functions for companies with fast growth trajectories such as Genentech and Facebook, and her experience will be valuable to Zosano as we plan for success." Elaine M
FREMONT, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the appointment of Kathy McGee, an accomplished biopharmaceutical executive, to its board of directors. Ms. McGee brings experience from a broad range of leadership roles across operations, strategic planning, manufacturing and supply chain management, quality and regulatory affairs and new product development. "Kathy is an exceptional addition to the board, bringing deep experience across many functional areas, and we are thrilled to have her join our board," said Steven Lo, president and chief executive officer of Zosano. "As we work to
25-NSE - Zosano Pharma Corp (0001587221) (Subject)
8-K - Zosano Pharma Corp (0001587221) (Filer)
8-K - Zosano Pharma Corp (0001587221) (Filer)
4 - Zosano Pharma Corp (0001587221) (Issuer)
4 - Zosano Pharma Corp (0001587221) (Issuer)
4 - Zosano Pharma Corp (0001587221) (Issuer)
SC 13G - Zosano Pharma Corp (0001587221) (Subject)
FREMONT, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that on June 1, 2022 it filed a voluntary petition for relief under chapter 11 of title 11 ("Chapter 11") of the United States Bankruptcy Code (the "Bankruptcy Code") in the United States Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"), thereby commencing a Chapter 11 case for the company. Zosano continues to operate its business as a "debtor-in-possession" under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and orders of the Bankruptcy Court. Zosano
PRESS RELEASE Emergex Vaccines Announces the Successful Coating of its Novel CD8+ T cell Adaptive COVID-19 Vaccine onto Zosano Pharma's Micro-Needle Patch Emergex's COVID-19 and Dengue CD8+ T cell Adaptive vaccines are already in clinical trials Abingdon, Oxon, UK, 17th May 2022 – Emergex Vaccines Holding Limited (‘Emergex', or the ‘Company'), a clinical stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, today announced that its COVID-19 vaccine candidate has been successfully coated onto Zosano Pharma Corporation's (NASDAQ:ZSAN) proprietary microneedle patch system. Zosano's patch consists of
FREMONT, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2022. All share and per share information included in these financial results and statements has been retroactively adjusted to give effect to our April 11, 2022 1-for-35 reverse stock split. Zosano reported a net loss for the first quarter of 2022 of $33.4 million, or $7.86 per share on a basic and diluted basis, compared with a net loss of $8.1 million, or $2.73 per share on a basic and diluted basis, for the same quarter in 2021. Research and development expenses for the first quar